Skip to main content

Unable to load price data. Sorry.

¯\_(ツ)_/¯

Renovis, Inc. (NASDAQ:RNVS.DL)

CAPS Rating: No stars

The Company is a science-driven, biopharmaceutical company that seeks to discover, develop, and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

0 Outperform
0 Underperform
 

All-Star Players

0 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:RNVS.DL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

drwings (26.04)
Submitted October 24, 2006

Stroke drug NXY-059, if it works, is likely to be $3 billion-a-year seller. News on the drug, which was licensed in under a 15-percent royalty deal by Astro-zenica from Renovis is expected imminently because the last of more than 3,000 patients… More

Reply | Report this Post

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:RNVS.DL Summary

  • Sector:
    • Industry:
  • Tags:

Recent Community Commentary

Read the most recent pitches from players about RNVS.DL.

No one has written a Pitch for RNVS.DL stock yet. Tell us why you think RNVS.DL will outperform or underperform against the market.

Leaderboard

Find the members with the highest scoring picks in RNVS.DL.

No players have picked RNVS.DL yet. Tell us why you think RNVS.DL will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for RNVS.DL.